Takeda: Positive CHMP Opinion for ADCETRIS for Hodgkin Lymphoma

– If Authorized in Europe, ADCETRIS in Combination with AVD (Adriamycin, Vinblastine and Dacarbazine) Will Be the First New Treatment Regimen Available for Adult Patients with Previously Untreated CD30+ Stage IV Hodgkin Lymphoma in Decades –

– Opinion Based on Positive Phase 3 ECHELON-1 Study Results, Which Demonstrated ADCETRIS Combination Improved Outcomes and Reduced the Need for Additional Treatment in Adult Patients Versus ABVD (Adriamycin, Bleomycin, Vinblastine and Dacarbazine), a Current Standard of Care –

https://www.marketscreener.com/TAKEDA-PHARMACEUTICAL-CO-6491073/news/Takeda-Pharmaceutical-Receives-Positive-CHMP-Opinion-for-ADCETRIS-brentuximab-vedotin-for-the-T-27756437/